References
1. Forlenza G et al. First Outpatient Evaluation of a Tubeless Automated Insulin Delivery System with Customizable Glucose Targets in Children and Adults
with Type 1 Diabetes. Diabetes Technology & Therapeutics. 2021;23(6). 2. Boughton CK, Hartnell S, Allen JM, Fuchs J, Hovorka R. Training and Support
for Hybrid Closed-Loop Therapy. Journal of Diabetes Science and Technology. September 2020. doi:10.1177/1932296820955168 3. American Diabetes
Association. 7. Diabetes Technology: Standards of Medical Care in Diabetes - 2021. Diabetes Care 2021; 44(Suppl.1); S85-S99.
Medical Disclaimer: This handout is for information only and is not a substitute for medical advice and/or services from a healthcare provider. This handout may not be relied upon in any way in
connection with personal healthcare related decisions and treatment.
© 2022 Insulet Corporation. Omnipod and the Omnipod 5 logo are trademarks or registered trademarks of Insulet Corporation in
the United States of America and other various jurisdictions. All rights reserved. The Bluetooth
®
word mark and logos are registered
trademarks owned by the Bluetooth SIG, Inc. and any use of such marks by Insulet Corporation is under license. Dexcom and Dexcom G6
are registered trademarks of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners.
The use of third-party trademarks does not constitute an endorsement or imply a relationship or other afliation.
INS-OHS-09-2021-00012 V 3.0
Insulet Corporation
100 Nagog Park, Acton, MA 01720
800-591-3455 • omnipod.com
To Previous Page
